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OBJECTIVE— This study analyzed which definition of the metabolic syndrome is more
predictive of cardiovascular events in both diabetic and nondiabetic members of a population-
based sample.
RESEARCH DESIGN AND METHODS— A 10-year, longitudinal follow-up of the
Strong Heart Study cohort has been evaluated. The analysis included 3,945 participants (2,384
female) with complete data (1,700 with diabetes and 1,468 with arterial hypertension) for
evaluation of metabolic syndrome. Those with prevalent cardiovascular disease were excluded
(n 287, of whom 127 were female). Prevalence of metabolic syndrome was assessed based on
the World Health Organization (WHO), the National Cholesterol Education Program Adult
Treatment Panel (NCEP ATP) III, and International Diabetes Federation (IDF) definitions. The
main outcome was 10-year incidence of combined fatal and nonfatal cardiovascular events,
including stroke, coronary heart disease, and congestive heart failure.
RESULTS— Fatal and nonfatal cardiovascular events occurred in 1,120 participants. After
adjusting for age, sex, and diabetes, metabolic syndrome by all definitions was significantly
associated with higher incidence of cardiovascular events (all P  0.0001). In nondiabetic
individuals, incident cardiovascular event rates were about 30–40% higher in those with met-
abolic syndrome, without a significant difference among definitions (0.03  P  0.001), and
remained significant in WHO and NCEP ATP III definitions even after further adjustment for
obesity, hypertension, and low HDL cholesterol. In the diabetic group, metabolic syndrome risk
for cardiovascular events was greatest using the WHO definition (P 0.002 vs. other models).
CONCLUSIONS— In individuals without diabetes, metabolic syndrome is associated with
incident cardiovascular disease, especially with WHO and NCEP ATP III definitions. Metabolic
syndrome also predicts higher cardiovascular
event rates in diabetic participants, a predic-
tion that is greatest using the WHO definition.
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The metabolic syndrome representsclusters of cardiovascular risk fac-tors, assuming that cardiovascular
risk is amplified more than is expected
from the effect of single risk factors (1).
Many studies support the utility of this
definition (2,3), but others have ques-
tioned the incremental utility of this ap-
proach (4).
An element of potential confusion
concerning the real prognostic utility of
defining metabolic syndrome is the avail-
ability of several definitions (5–9), reflect-
ing different strategies, either identifying
a main characteristic as a necessary fac-
tor (5,7,9) associated with other variable
risk factors or accepting varied combina-
tions of characteristics (6,8). Other differ-
ences may also be important, including
partition values and methods to define
abnormalities.
At present, few data exist comparing
the correlates and prognostic significance
of the definitions of metabolic syndrome
in the same population. Accordingly, we
compared the ability of the most used def-
initions of metabolic syndrome to predict
cardiovascular events in the Strong Heart
Study (SHS) cohort.
RESEARCH DESIGN AND
METHODS— The SHS is a popula-
tion-based cohort study of cardiovascular
risk factors and disease in 4,549 American
Indians from three communities in Ari-
zona, seven in Southwestern Oklahoma,
and three in South and North Dakota, as
extensively described (10–14). Partici-
pants seen during the baseline exam, in
1989–1992, were representative of the
source population (15).
For the present analysis, individuals
with prevalent cardiovascular disease
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(n 287, 127 of whom were female) were
excluded. Prevalent and incident cardio-
vascular events (cardiovascular death,
stroke, congestive heart failure, myocar-
dial infarction, and coronary heart disease
[coronary angiography, combination of
typical symptoms with positive treadmill
tests or abnormal imaging stress test, or
revascularization procedures]) were con-
firmed by the SHS mortality and morbid-
ity committees, using specified criteria for
causes of fatal and nonfatal cardiovascular
events (16).
Diabetic participants were included;
participants with fasting triglyceride lev-
els 750 mg/dl were excluded. Thus,
3,945 participants (2,384 women) with-
out prevalent cardiovascular disease and
available data (1,700 with diabetes and
1,468 with hypertension) were included
in the analysis.
Laboratory tests and definitions of
metabolic syndrome
Fasting plasma glucose and lipid profile
were measured by standard methods
(12). Diabetes (fasting plasma glucose
126 mg/dl or antidiabetes treatment)
and impaired fasting glucose (110 mg/
dl) were diagnosed by 1997 American Di-
abetes Association recommendations
(17). Obesity was classified based on the
1998 National Institutes of Health guide-
lines (18) (BMI 30 kg/m2). Central fat
distribution was based on waist circum-
ference and defined in relation to sex-
specific cutoff points used in the different
definitions examined in this study (Table
1). For the International Diabetes Feder-
ation (IDF) definition, the values pro-
posed for Europids have been adopted. A
random urine sample was used to mea-
sure albumin and creatinine (11).
Table 1 shows the criteria used to de-
fine metabolic syndrome by three guide-
lines: those by the World Health
Organization (WHO) (5,9), the National
Cholesterol Education Program Adult
Treatment Panel (NCEP ATP) III (6), and
the IDF (9). Insulin-glucose homeostasis
for the WHO definition was estimated by
the homeostasis model assessment
(HOMA) equation (19). Based on the
WHO recommendation, a partition value
for HOMA index was arbitrarily deter-
mined in the nondiabetic SHS partici-
pants as the lower boundary of the highest
tertile (4.3). Thus, insulin resistance sta-
tus was defined as the presence of type 2
diabetes or fasting glucose 110 mg/l or
HOMA index 4.3. Hypertension was
defined by Joint National Committee VII
criteria (blood pressure 140/90 mmHg
or use of antihypertensive treatment).
Statistical analysis
Data were analyzed using SPSS (version
12.0; SPSS, Chicago, IL). Data are ex-
pressed as means  SD. All variables de-
viating from normal distribution were log
transformed before parametric statistics.
The urinary albumin-to-creatinine ratio is
presented as median (interquartile
range). An indicator variable was in-
cluded for the three field centers: Arizona,
South and North Dakota, and Oklahoma.
Participants were categorized into groups
according to the presence of metabolic
syndrome, defined by each definition.
The 10-year relative risk of combined
fatal and nonfatal cardiovascular events
Table 1—Definition of metabolic syndrome according according to the WHO, NCEP ATP III, and IDF
Factor WHO (main criterion  2 factors)*
ATP III (any
combination of 3 factors) IDF (main criterion  2 factors)
BMI (kg/m2) 30 — —
Abdominal obesity (men/women) Waist-to-hip ratio 0.9/0.85 Waist 102/88 cm Waist >94/80 cm†
Triglycerides (mg/dl) 150 150 150
HDL cholesterol (mg/dl) (men/women) 35/39 40/50 40/50
Blood pressure (mmHg) 140/90 130/85 140/90 or 130/85
HOMA‡ >4.3 — —
Type 2 diabetes Present — Present
Fasting glucose (mg/dl) >110 110 100
Fasting insulin — — —
Urinary albumin excretion 20 g/min or 30 mg/g creatinine — —
Sine qua nonfactors are in bold. *According to the WHO, either BMI or abdominal obesity represents one criterion. †Ethnic group waist circumference (as measure
of central obesity): Europid men94 and women80 cm; South Asian men90 and women80 cm; Chinese men90 and women80 cm; and Japanese men
85 and women90 cm. Ethnic South and Central American populations use South Asian recommendations until more specific data are available. Sub-Saharan
African populations use European data until more specific data are available. Eastern Mediterranean and Middle East (Arab) populations use European data until
more specific data are available. ‡According to the WHO, HOMA, type 2 diabetes, and fasting glucose are alternatives, fulfilling one criterion.
Table 2—Metabolic syndrome by different definitions (see Table 1): concordance and differences in blood pressure and urinary albumin-to-
creatinine ratio
Prevalence of
metabolic syndrome
Systolic blood
pressure (mmHg)
Diastolic blood
pressure (mmHg) Urinary albumin/creatinine ratio
Men Women No MetS MetS
No
MetS MetS No MetS MetS
WHO 48 53 122  16 133  20 75  9 79  10 6.60 (3.40–12.5) 28.18 (7.62–153.74)
ATP III 44 63 121  17 132  20 75  9 78  10 6.96 (3.57–15.73) 16.55 (6.38–82.58)
IDF 59 73 120  16 131  19 74  9 78  10 6.90 (3.59–15.94) 13.62 (5.54–62.25)
Data are means  SD, percentages, or median (interquartile range). MetS, metabolic syndrome.
Metabolic syndrome
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was estimated for each definition. Log-
cumulative hazard functions were com-
puted by Cox regression, adjusting for age
(years), field center, sex, and diabetes.
Additional models were also adjusted for
the other components of metabolic syn-
drome. Cox regression was also run sep-
arately for diabetic and nondiabetic
participants.
To compare the independent prog-
nostic effect of metabolic syndrome by the
three definitions, likelihood functions
were compared (20). The difference be-
tween two 2 log likelihoods has a 2
distribution, which, for this comparison,
has 1 d.f. (20). Two-tailed 	 0.01 iden-
tified significant differences among the
three models.
RESULTS— Table 2 shows that the
IDF definition yielded the highest preva-
lence of metabolic syndrome in both men
and women. The WHO definition re-
sulted in a similar proportion of metabolic
syndrome in men and women, whereas
NCEP ATP III and IDF showed a substan-
tially higher prevalence in women, with
the greatest sex difference by the NCEP
ATP III definition (both P 0.0001). The
coefficient of concordance (k) among the
different definitions in the recognition of
metabolic syndrome status was not excel-
lent: 0.56 and 0.59 for men and women
between WHO and NCEP ATP III, 0.58
and 0.77 between NCEP ATP III and IDF,
and only 0.49 and 0.50 between WHO
and IDF definitions, respectively.
Table 2 also shows that, due to differ-
ing high blood pressure criteria, the
WHO definition was associated with
slightly higher blood pressure levels than
was NCEP ATP III or IDF. Urinary albu-
min-to-creatinine ratio was highest in
participants with metabolic syndrome by
the WHO definition (including this pa-
rameter among criteria for definition), but
also higher in the NCEP ATP III and IDF
definitions (all P  0.0001), than in par-
ticipants without metabolic syndrome.
The criteria for adiposity proposed by
the WHO identified 83% of participants
with central fat distribution in the absence
of metabolic syndrome (compared with
96% in those with metabolic syndrome).
The difference between groups without
(66% with central fat) vs. with metabolic
syndrome (100% with central fat) was
more accentuated in the IDF and maximal
with the NCEP ATP III definition (50 vs.
91%, respectively). In all definitions, one-
half or more of individuals free of the syn-
drome exhibited central fat distribution.
Cardiovascular risk in the metabolic
syndrome
Over the follow-up time (119  45
months), 1,157 cardiovascular events
were adjudicated, including 176 strokes,
299 myocardial infarctions, 226 other
clinical manifestations of coronary heart
disease, 394 cases of congestive heart fail-
ure, and 62 sudden deaths. The incidence
of combined fatal and nonfatal cardiovas-
cular events was 2.38-fold greater in par-
ticipants with than in those without
metabolic syndrome (95% CI 2.04–2.73)
by the WHO definition, 2.12-fold greater
(1.81–2.47) by the ATP III definition, and
1.92-fold greater (1.62–2.27) by the IDF
definition (all P 0.0001). Table 3 shows
that metabolic syndrome was always as-
sociated with increased rate of cardiovas-
cular events (all P  0.0001), even
independent of age, sex, field center, and
presence of diabetes. The regression
model including metabolic syndrome by
the WHO definition was significantly
more predictive than the other models,
including the other definitions (both P
0.002).
Alternative Cox regression models
adjusted for obesity, low HDL choles-
terol, and hypertension, in addition to the
covariates used in the previous model. Al-
though reduced, the hazard ratios (HRs)
of metabolic syndrome remained statisti-
cally significant for the definitions by the
NCEP ATP III (HR 1.28 [95% CI 1.04–
1.56], P  0.02) and the WHO (1.35
[1.11–1.64], P  0.002) but not by IDF
(1.12 [0.92–1.36], P  0.2).
Cardiovascular risk in diabetic and
nondiabetic subjects
In both diabetic and nondiabetic partici-
pants, the prognostic effect of metabolic
syndrome was confirmed for all three def-
initions (Table 4). The HR for incident
composite fatal and nonfatal events was

30–40% higher in nondiabetic partici-
pants with metabolic syndrome, by all
definitions, without significant differ-
ences among them (Fig. 1). In contrast, in
diabetic participants, the HR for the met-
abolic syndrome was not statistically sig-
nificant using the IDF definition (26%
increased risk), was higher with the NCEP
ATP III definition (43% increased risk),
and was highest with the WHO definition
(near-doubled risk), a difference that was
statistically significantly (P  0.001).
CONCLUSIONS— This study dem-
onstrates that in the SHS cohort, meta-
bolic syndrome by all three examined
Table 3—The 10-year hazard for incident fatal/nonfatal cardiovascular associated with met-
abolic syndrome, according to three different definitions, adjusting for age, sex, field center,
and diabetes
Diabetes No diabetes P 2 log likelihood
WHO 2.29 (1.97–2.67) 1.54 (1.32–1.80) 0.0001 15,033
ATP III 2.45 (2.12–2.84) 1.42 (1.22–1.66) 0.0001 15,043
IDF 2.59 (2.25–2.98) 1.37 (1.17–1.61) 0.0001 15,049
Data are HRs (95% CI) for metabolic syndrome. Comparison between likelihood functions has been done for
1 d.f.
Table 4—The 10-year hazard for incident fatal/nonfatal cardiovascular events in separate
nondiabetic and diabetic subgroups of the SHS, in relation to presence of metabolic syndrome,
according to 3 different definitions, adjusting for age, sex, and field center
Increase in
cardiovascular risk 95% CI P 2 log likelihood
Nondiabetic
WHO 1.28 1.03–1.59 0.03 5,309
ATP III 1.40 1.13–1.73 0.002 5,305
IDF 1.44 1.17–1.78 0.001 5,302
Diabetic
WHO 1.94 1.51–2.47 0.0001 8,381
ATP III 1.43 1.13–1.81 0.003 8,404
IDF 1.26 0.99–1.62 0.07 8,410
Comparison between likelihood functions has been done for 1 d.f.
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definitions is independently associated
with a significantly greater rate of incident
composite fatal and nonfatal cardiovascu-
lar events and is a marker of preclinical
cardiovascular disease, represented by
the increased urinary albumin-to-
creatinine ratio. The independent associ-
ation of metabolic syndrome with
cardiovascular events was seen in popu-
lation strata with or without diabetes.
In participants without diabetes, in-
creased cardiovascular risk is indepen-
dently associated with metabolic
syndrome, suggesting that this diagnosis
can help identify high-risk individuals.
Similarly, among diabetic individuals,
recognition of the metabolic syndrome
impressively enhanced the prediction of
cardiovascular events, consistent with
National Health and Nutrition Examina-
tion Survey III results (21), where the age-
adjusted prevalence of coronary heart
disease in the diabetic population without
metabolic syndrome (8%) was similar to
that in subjects without diabetes or met-
abolic syndrome (9%), while increasing
to 14% in nondiabetic subjects with met-
abolic syndrome and to 19% in those with
both conditions. However, independent
of the presence of full-fledged metabolic
syndrome, attention to all cardiovascular
risk factors is paramount in the presence
of diabetes. Compared with nondiabetic
populations, detecting the full presenta-
tion of metabolic syndrome might be less
important for decision making when dia-
betes coexists with even one additional
risk factor.
This study identifies similarities
among the three definitions of metabolic
syndrome but also reveals differences. In
the whole population, combining partic-
ipants with or without diabetes, the
model using the WHO definition was a
better predictor than models using NCEP
ATP III or IDF definitions, with IDF ex-
hibiting the lowest fit. When forcing sin-
gle cardiovascular risk factors into the
Figure 1—Adjusted cumulative hazard in participants with (—) or without () metabolic syndrome, in nondiabetic or diabetic participants,
according to diagnostic criteria issued by the WHO (top panel), ATP III (middle panel), or IDF (bottom panel).
Metabolic syndrome
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proportional hazard model, only the
WHO and ATP III definitions maintained
an independent prognostic impact,
whereas the IDF definition did not, pos-
sibly due to lower specificity associated
with the generally lower partition values
for single factors.
In nondiabetic participants, the risks
predicted by the three definitions were
not statistically different. In contrast, a
substantial difference was evident among
diabetic participants, with the WHO def-
inition significantly superior to those of
both the NCEP ATP III and IDF (the HR of
which was not statistically significant).
Although the NCEP ATP III definition
was not intended for diabetic individuals,
it should be noted that it performed well
in participants with or without diabetes,
though slightly less well than WHO in
those with diabetes.
To evaluate correctly the implications
of these findings, both the characteristics
of the SHS population and the differences
among the different definitions of meta-
bolic syndrome have to be taken into ac-
count. The American Indian population
of the SHS is characterized by higher
prevalence of obesity than the overall
population in the U.S. and Europe (12),
though this difference is rapidly attenuat-
ing (22–25). As a consequence, in the
SHS cohort, the distribution of measures
of adiposity is skewed toward higher val-
ues, similar to findings in hypertensive
populations (26). Due to the high preva-
lence of obesity, the adopted measures of
fatness in the WHO definition do not dis-
criminate well between participants with
or without the metabolic syndrome. Also
with the other definitions, substantial
proportions of participants without met-
abolic syndrome exhibited central fat dis-
tr ibution, maximal with the IDF
definition, which uses very low partition
values for waist girth. Thus, in the context
of a population with very high prevalence
of obesity, measures of adiposity or ab-
dominal obesity do not strongly separate
individuals with or without metabolic
syndrome, since obesity is also highly
prevalent among individuals without
metabolic syndrome.
The present analysis extends a previ-
ous study of metabolic syndrome in non-
diabetic SHS participants. That analysis
did not report significant independent as-
sociations between metabolic syndrome
(by the NCEP ATP III definition) and car-
diovascular risk (27), but it included only
4.2 years of follow-up and was limited to
some cardiac events. In contrast, the
present analysis also included diabetic
participants, the follow-up was substan-
tially longer, and all clinical manifesta-
tions of cardiovascular disease, including
cerebrovascular events and congestive
heart failure, were considered as end
points. In particular, incident congestive
heart failure (394 adjudicated events)
could be very important, because heart
failure is a relevant end point for obesity
(28–30). Overall, our findings suggest
that the metabolic syndrome may take
several years to manifest its effects on clin-
ical events (as Fig. 1 also suggests).
In conclusion, the NCEP ATP III and
WHO (but not IDF) definitions of meta-
bolic syndrome predict cardiovascular
disease independently of single compo-
nents of the syndrome; their value may be
similar in individuals without diabetes,
but in diabetes the WHO definition seems
to be more useful. Results of these analy-
ses, obtained in a population with high
prevalences of obesity and diabetes, are
likely applicable to other populations of
different ethnicities in which there is an
epidemic rise of prevalences of over-
weight and obesity (31), triggering diabe-
tes and other metabolic abnormalities
(32). The identification of the metabolic
syndrome can be valuable to focus aggres-
sive intervention strategies, especially
when diabetes has not yet occurred.
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